[미래에셋 김승민] 인상적인점

1. 다른 아토피 바이오의약품(사노피 듀픽센트, 릴리 앱글리스 – IL-4/13 항체) 대비 결막염(conjunctivitis, 주로 발생하는 부작용) 0건이라는 점(IL-18 타겟의 기전적 차이) “Importantly, there were no observed cases of conjunctivitis, which is a key differentiator versus other biologics in atopic dermatitis.” 2. IL-18은 upstream inflammatory amplifier이기에 다른 아토피 항체(IL-4/13)들이 침투하지 못한 IBD도 가능성 ““IL-18 is a well characterized inflammatory cytokine which plays a key role in various immune processes and acts as a key therapeutic target for Atopic Dermatitis and other chronic inflammatory diseases.” “In parallel, we are also evaluating additional indications where IL-18 is believed to play a key role, including ulcerative colitis and other chronic inflammatory diseases.” 3. 기존 IL-18 항체보다 SAFA 활용했기에 조직 침투, 반감기 측면에서 장점 “This design is intended to improve tissue distribution, extend half-life, maintain high affinity, and selectively bind to IL-18.” “We believe this approach offers advantages over traditional monoclonal antibodies that have attempted to antagonize IL-18.” “Including the smaller molecular weight and improved penetration into inflamed tissues. 4. 에보뮨-에이프릴 계약 구조는 라이선스 조건은 시장 평균 수준 “I think the best way to answer that question is we've negotiated a very on-market and competitive license agreement, and there's nothing abnormal or unusual in our upstream license obligations“ 5. (과거 dermira는 genentech으로부터 앱글리스(lebrikizumab IL-13)을 라이선스-인해 개발하다, 릴리에게 $1.1bn(약 1.5조원) 규모에 매각 있고 Dermira의 공동창업자가 회사 매각 후 창업한 회사가 Evommune이기에) 우리는 lebrikizumab 개발 경험을 활용한다. “As we advance EVO301 into a phase 2b sub-Q study in Atopic Dermatitis, we will leverage the insights from this study and our experience with biologic dosing in the past, such as Lebrikizumab, now Ebglyss, which Luis and the team developed at Dermira.” Lebrikizumab 개발 경험을 활용한다 “With only two doses of EVO301 administered at day 1 and 28, we believe these are remarkable efficacy data.” 6. 2b에서는 “biologics-experienced 환자에게도 효과 기대”